Cancer Genetic Testing in Ethnic Populations

Launched by MAYO CLINIC · Jul 14, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how cancer genetic testing can be used among different ethnic groups. Researchers are looking at individuals and families who may be at risk for certain types of cancer, such as breast, skin, and brain cancers, among others. By identifying specific cancer genes, the study aims to help understand who might be at higher risk for developing cancer and how to tailor screening and prevention efforts for these groups.

To participate, individuals must be at least 18 years old and have been diagnosed with a solid tumor cancer. They should also identify as part of various ethnic populations, including Hispanic, Native American, African American, and Asian backgrounds. Participants will be asked to provide a blood sample for testing. The study is currently recruiting participants, and those who choose to take part will help contribute valuable information that could improve cancer care for their communities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients at least 18 years of age
• • Individuals diagnosed with any solid tumor cancer including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)/brain, head/neck, musculoskeletal or cancer of unknown primary; and presenting to Mayo Clinic (MC Arizona or MC Florida) for clinical management/treatment; and patients receive genetic testing as described above
• • Self-identified as being from various ethnic populations including Hispanic/Latino, Native American/Alaskan, African American (including of African descent), Asian and other European populations
• • Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s)
• • Individuals have agreed to participate and signed the study informed consent form
• Exclusion Criteria:
• • Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic and available for review by the research coordinator at time of consent
• • Past or current history of hematological cancer (including leukemias, multiple myeloma)
• • All bone marrow transplants